163
Views
3
CrossRef citations to date
0
Altmetric
Letters to the Editor

More than ten percent of relapses occur after five years in AML patients with NPM1 mutation

, , , , , , , , , , , & show all
Pages 1226-1229 | Received 27 Aug 2019, Accepted 14 Dec 2019, Published online: 05 Feb 2020
 

Disclosure statement

CR has received research grants from Amgen, Novartis, Celgene, Jazz Pharmaceuticals, Agios, Chugai, Sunesis, Astellas and MaatPharma and is an advisor for Abbvie, Sunesis, Janssen, Jazz, Novartis, Celgene, Astellas, Daiichi-Sankyo, Macrogenics and Pfizer. FH is an advisor for Amgen, BMS, Celgene, Incyte, Jazz Pharma, Novartis, and Pfizer. ST and ED are advisors for Novartis. SB is an advisor for Daiichi-Sankyo, Sanofi, Jazz Pharmaceuticals and Astellas.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.